ADOCIA: Showcasing Innovation at Upcoming Investor Conferences

Adocia, a clinical-stage biopharmaceutical company specializing in innovative therapeutic solutions for diabetes and obesity, has announced its participation in several upcoming investor conferences in 2025. These events provide an opportunity for the company to showcase its cutting-edge drug candidates and technology platforms to potential investors, fostering partnerships and collaborations that could accelerate its growth and market position.

Adocia's CEO, Olivier Soula, will participate in the Annual BioPharma Obesity Innovation Forum in January 2025, where he will discuss the company's focus on obesity and metabolic diseases. During this event, Adocia will highlight its AdoShell® and AdOral® platforms, which have the potential to revolutionize the treatment of these conditions. AdoShell® is an immunoprotective biomaterial for cell transplantation, while AdOral® is an oral peptide delivery technology that enables the administration of peptides through the oral route.



In addition to the BioPharma forum, Adocia will also attend the JPM 2025 – 43rd Annual Healthcare Meeting in January 2025. This premier healthcare event will provide Adocia with the opportunity to engage with a broad range of investors and industry leaders, showcasing its broad portfolio of drug candidates based on four proprietary technology platforms: BioChaperone®, AdOral®, AdoShell®, and AdoGel®. These platforms have the potential to transform the treatment of diabetes and obesity, offering more effective and convenient solutions for patients.



Adocia's participation in these conferences comes at a critical time for the company, as it prepares to announce its financial calendar for 2025. The company's recent financial performance and upcoming milestones, such as the publication of revenue for Q4 2024 in February 2025 and the annual shareholders' meeting in June 2025, will be discussed during these events. By updating investors on its financial progress and plans for the year, Adocia can build confidence in its future prospects and secure partnerships that will drive its growth.

In conclusion, Adocia's participation in upcoming investor conferences in 2025 presents a strategic opportunity for the company to showcase its innovative drug candidates and technology platforms to potential investors. By engaging with investors and industry leaders at these events, Adocia can foster partnerships and collaborations that will accelerate its growth and strengthen its market position in the diabetes and obesity treatment landscape. As the company continues to develop its pipeline and achieve key milestones, investors can expect to see significant progress in its mission to provide innovative therapeutic solutions for these conditions.